Royalty Report: Drugs, Skin care, Acne – Collection: 221650


Curated Royalty Rate Report
Category: Technology Licenses, Created On: 2022-04-28, Record Count: 3


This collection of transactions and supporting information was developed using our AI algorithm to curate similar royalty reports into a cohesive collection to support your licensing, transfer pricing or other transaction scenarios where documented royalty rates and/or deal terms are important.
Category: Technology Licenses
Created On: 2022-04-28
Record Count: 3

Primary Industries

  • Drugs
  • Skin care
  • Acne
  • Therapeutic
  • Drug Discovery
  • Dermatology

IPSCIO Report Record List

Below you will find the records curated into this collection.  This summary includes the complete licensed property description so that you can review and determine if this collection covers the topics, technology or transaction type that is relevant for your needs.  The full report will include all relevant deal data such as the royalty base, agreement date, term description, royalty rates and other deal terms.  For reference, here is a sample of a full IPSCIO curated royalty rate report: Sample Report

IPSCIO Record ID: 221650

License Grant
The Company assumed, following the transfer of an in-process research and development product candidate (hereafter — the product), an agreement for the development, manufacturing and commercialization of this product. According to this agreement, the Licensor will conduct all regulatory, scientific, clinical and technical activities necessary to develop the product.
License Property
The lead product candidate, TWIN, is a novel, once-daily, non-antibiotic topical cream that we are developing for the treatment of acne vulgaris, or acne. The company recently completed a 726 subject, double-blind, placebo-controlled, six-arm, multi-center Phase II clinical trial designed to assess the safety and efficacy of TWIN in subjects with facial acne. In this trial, TWIN demonstrated statistically significant improvements in all pre-defined co-primary and secondary efficacy endpoints, as compared to vehicle.  Subject to an End of Phase II meeting to be scheduled with the FDA, we plan to initiate two pivotal Phase III trials for TWIN in the United States in the second half of 2018 and expect to report top-line data from these trials in 2019. The other branded product candidates are SIRS-T, a topical cream containing encapsulated tretinoin for the potential treatment of acne; and VERED, a potential treatment for subtype II rosacea.

The product candidate pipeline consists of late-stage branded product candidates that leverage the proprietary, silica-based microencapsulation technology platform, and several generic product candidates across multiple indication.

Licensor is a dermatology company focused on identifying, developing and commercializing branded and generic topical drug products for the treatment of skin diseases.

Field of Use
This agreement pertains to the drug industry relating to the treatment of skin diseases.

IPSCIO Record ID: 375357

License Grant
This Agreement is for the collaborative development and commercialization of the DFD-29 program (minocycline HCl 40 mg capsules) for the treatment of rosacea. Licensee acquired global commercialization rights to DFD-29, including in the U.S. and Europe, except that Licensor has retained certain rights to the program in select markets including Brazil, Russia, India, and China. Licensor will provide development support including the monitoring of two Phase III clinical trials.
License Property
Through this collaboration, Licensee will work together with Licensor to complete the development of DFD-29, which includes conducting two Phase III studies to assess the efficacy, safety and tolerability of oral DFD-29 for the treatment of rosacea and the regulatory submission of a new drug application.

DFD-29 is a modified release oral minocycline that is being evaluated for the treatment of inflammatory lesions of rosacea.

Field of Use
Field of use is for the treatment of a skin disease relating to rosacea.  Rosacea is a common skin condition that causes blushing or flushing and visible blood vessels in your face.

IPSCIO Record ID: 377000

License Grant
This Agreement is for the purchase of Accutane with a term of 10 years. The agreement contains customary representations, warranties, and indemnities.
License Property
Accutane® is an oral isotretinoin drug for the treatment of severe recalcitrant acne. Accutane® (isotretinoin 20mg, 30mg, and 40mg capsules USP) is indicated for treating severe recalcitrant nodular acne. Accutane is used to treat a type of severe recalcitrant nodular acne that has not been helped by other treatments, including antibiotics. Severe recalcitrant nodular acne occurs when many red, swollen, tender lumps form in the skin. Patients with severe nodular acne are at higher risk of scarring. Accutane belongs to a class of drugs that affects all four major pathogenic processes in acne increased sebum production, irregular follicular desquamation, propionibacterium acnes proliferation and inflammation. Accutane has achieved a strong market position and is well known in the dermatology community.
Field of Use
Field of use is for the treatment of recalcitrant nodular acne.
Disclaimer: The information gathered from RoyaltySource® database was sourced from the U.S. Securities and Exchange Commission EDGAR Filings and other public records. While we believe the sources to be reliable, this does not guarantee the accuracy or completeness of the information provided. Further, the information is supplied as general guidance and is not intended to represent or be a substitute for a detailed analysis or professional judgment. This information is for private use only and may not be resold or reproduced without permission.